바이오인

No

Date

Investors/

Licensee

Service Provider/

Licensor

Assets

MoA

Indication

Stage

Value

(USD Mn)

 1

7/4

AstraZeneca

Modella AI

Modella AI’s

multi-modal

foundation

models

-

Oncology

-

-

n/d

 2

7/22

AimedBio

GI Innovation

GI-102

IL2RG agonist, CTLA4 agonist,

IL2RB agonist

Oncology

Recurrent glioblastoma

Phase II

n/d

 3

7/24

Novartis

Matchpoint

Therapeutics

Small molecules

Oral inhibitors,

developed based on

Advanced Covalent

Exploration (ACE) platform

Immunology

Multiple Inflammatory diseases

Preclinical

1,060

 4

7/24

Eli Lilly

GateBioscience

Small molecule

n/d

n/d

-

Discovery

856

 5

7/27

GSK

Jiangsu Hengrui

Pharmaceuticals

HRS-9821

11 programmes

PDE3/4 inhibitor

Unspecified

Respiratory

diseases

Unspecified

Chronic Obstructive Pulmonary

disease

Phase I

Discovery

12,500

 6

7/28

Boehringer

Ingelheim

Re-Vana

Therapeutics

dirloctocogene

samoparvovec

Coagulation Factor VIII

Activator

Hematological Disorders

Hemophilia A (Factor VIII Deficiency)

Phase II

1,000

 7

7/30

Madrigal

Pharmaceuticals

CSPC

Pharmaceutical

SYH-2086

Oral GLP1R agonist

Gastrointestinal

disease

Metabolic Dysfunction-Associated

Steatohepatitis (MASH)

Preclinical

2,120

 8

7/30

Kissei

Pharmaceutical

Viridian

Therapeutics

Veligrotug

VRDN-003

IGF1R antagonist

IGF1R antagonist

Oncology

Ophthalmology

Ophthalmology

Breast Cancer, Liver Cancer,

Graves' Ophthalmopathy

Graves' Ophthalmopathy

Phase III

385

 9

7/31

DR.Noah

Biotech

Thermo Fisher

Scientific

ARK

Quadrant 2

Noah’s proprietary AI drug

discovery platform

Thermo Fisher’s AI-driven

formulation technology

-

Rare diseases

-

n/d

No

Date

Acquires

Issuer

Assets

MoA

Indications

Status

Value

(USD Mn)

 1

7/1

Concentra Biosciences

IGM Biosciences

Immunology n/d

Inflammation n/d

being developed based on IgM antibody technology platform

Immunology

Inflammation

Autoimmune Disorders

Discovery

75

 2

7/8

Recursion Pharmaceuticals

Rallybio

REV-102

ENPP1 Inhibitor

Genetic Disorders,

Metabolic Disorders

Hypophosphatasia

Preclinical

25

 3

7/16

Cystic Fibrosis Foundation Therapeutics

Prime Medicine

prime editor

CFTR activator developed using gene editing technology

Respiratory

Cystic Fibrosis

Preclinical

24

 4

7/17

I-Mab

Bridge Health Biotech

givastomig

CLDN18 inhibitor,

TNFRSF9 agonist

Oncology

gastric cancer, solid tumor

Phase I

6.88

 5

7/21

Concentra Biosciences

iTeos Therapeutics

EOS-850

Adenosine Receptor A2a

Antagonist

Oncology

Solid tumors,

non-small cell lung cancer

Phase II

384.5